This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.
Medscape Medical News